STOCK TITAN

Beam Therapeutics (BEAM) Stock Price, News & Analysis

BEAM NASDAQ
Published by Stock Titan Data refreshed

Price Move History

Daily moves over 5%
56 252 sessions, November 20, 2025 to November 20, 2026
Largest daily move
+22.3% close of January 12, 2026
1-year change
+1.5% closing prices, November 20, 2025 to November 20, 2026
1-month change
-16.2% closing prices, October 20, 2026 to November 20, 2026

Company Description

Beam Therapeutics Inc. (Nasdaq: BEAM) is a biotechnology company developing precision genetic medicines through base editing. The company describes its goal as establishing a fully integrated platform for precision genetic medicines, bringing together gene editing, delivery and internal manufacturing capabilities. Beam’s gene editing technologies are anchored by base editing, a proprietary approach designed to enable precise, predictable and efficient single base changes at targeted genomic sequences without making double-stranded breaks in DNA.

According to the company, this base editing platform has the potential to support a wide range of therapeutic editing strategies. Beam is using this platform to advance a diversified portfolio of programs across hematology and liver-targeted genetic diseases. The company reports that it manages its business as a single operating segment and operates in the United States.

Precision genetic medicines and base editing platform

Beam states that its platform integrates gene editing tools, delivery technologies and internal manufacturing. Its base editing technology is described as enabling single base changes at specific genomic locations in a way that is designed to be precise and predictable. By avoiding double-stranded DNA breaks, Beam positions base editing as a next-generation gene editing approach for developing genetic medicines.

The company repeatedly highlights that it is values-driven and focused on using its science and platform to pursue life-long cures for patients with serious diseases. Beam’s disclosures emphasize precision, predictability and the potential for one-time treatments that aim to reverse underlying genetic causes of disease.

Hematology franchise and sickle cell disease programs

Beam is advancing a hematology franchise centered on sickle cell disease (SCD). One of its key programs is ristoglogene autogetemcel (risto-cel), formerly known as BEAM-101, an investigational genetically modified ex vivo base editing cell therapy for SCD with severe vaso-occlusive crises. Risto-cel consists of autologous CD34+ hematopoietic stem and progenitor cells that have been base-edited in the promoter regions of the HBG1/2 genes and are administered via a hematopoietic stem cell transplant procedure.

The risto-cel edit is designed to inhibit the transcriptional repressor BCL11A from binding to the HBG1/2 promoter without disrupting BCL11A expression. Beam reports that this is intended to increase production of non-sickling and anti-sickling fetal hemoglobin (HbF) and mimic naturally occurring variants seen in hereditary persistence of fetal hemoglobin. HbF is described as the predominant hemoglobin variant during development and early life.

The safety and efficacy of risto-cel are being evaluated in the ongoing BEACON Phase 1/2 trial, an open-label, single-arm, multicenter study in patients with SCD with severe vaso-occlusive crises. Beam has reported updated data from this trial in multiple scientific forums, including the European Hematology Association Congress and the American Society of Hematology (ASH) Annual Meeting. The company has also announced that the U.S. Food and Drug Administration (FDA) granted Regenerative Medicine Advanced Therapy (RMAT) designation and orphan drug designation to BEAM-101/risto-cel for the treatment of SCD.

Liver-targeted genetic disease franchise

Beam is also building a liver-targeted genetic disease franchise. The company describes a platform approach for single-course precision gene editing therapies for liver-targeted diseases by delivering base editors through intravenous infusion of lipid nanoparticles (LNPs), a clinically validated technology for delivering nucleic acid payloads to the liver.

Its lead liver-targeted program is BEAM-302, which Beam characterizes as a liver-targeting therapy for alpha-1 antitrypsin deficiency (AATD) designed to address the underlying pathophysiology of both liver and lung disease. In an open-label Phase 1/2 clinical trial in AATD, Beam has reported that treatment with BEAM-302 demonstrated in vivo genetic correction of a disease-causing mutation and established clinical proof of concept in AATD. The company has described dose-dependent correction of the mutation, restoration of production of functional corrected M-AAT, and reductions in the mutant Z-AAT protein.

Beam has stated that more than 25 AATD patients with lung and/or liver disease have been treated in the dose-exploration portions of the BEAM-302 Phase 1/2 trial. The company reports that the FDA granted RMAT designation and orphan drug designation to BEAM-302 and that BEAM-302 has been accepted into the FDA’s Chemistry, Manufacturing, and Controls Development and Readiness Pilot (CDRP) program. Beam has also disclosed that it reached alignment with the FDA on a potential accelerated approval pathway for BEAM-302 based on AAT biomarkers evaluated over 12 months.

Additional pipeline programs and platforms

Beyond risto-cel and BEAM-302, Beam is advancing additional programs built on its base editing and delivery capabilities. BEAM-301 is described as a program that aims to correct the R83C mutation in patients with glycogen storage disease type Ia (GSDIa). BEAM-301 is being evaluated in an open-label Phase 1/2 dose-exploration trial in patients with GSDIa.

Beam is also developing its ESCAPE (Engineered Stem Cell Antibody Evasion) platform. As part of ESCAPE, the company has introduced BEAM-103, an anti-CD117 monoclonal antibody being studied in a Phase 1 healthy volunteer trial. Beam describes ESCAPE as a potential alternative to genotoxic conditioning regimens in stem cell transplantation, with the aim of avoiding toxicity challenges associated with currently available conditioning regimens for patients with SCD and beta-thalassemia.

In addition, Beam has disclosed that it is investing in targeted LNPs for delivery of genetic payloads outside the liver, including to hematopoietic stem cells. The company has stated that multiple targeted LNPs for hematopoietic stem cell delivery have been identified and are in lead optimization.

Collaborations and strategic activities

Beam has participated in collaborations that leverage its mRNA and targeted lipid nanoparticle capabilities. The company reported that it contributed capabilities and technology in mRNA and targeted lipid nanoparticles to Orbital Therapeutics and that it held a common stock stake in Orbital. Beam has disclosed that Bristol Myers Squibb announced a definitive agreement to acquire Orbital Therapeutics, and Beam reported receiving closing cash consideration from that transaction, with the potential for additional consideration subject to escrow conditions.

Beam also reported that it acquired an early-stage life sciences company under an Agreement and Plan of Merger, as described in a Form 8-K filing. As consideration, Beam agreed to issue shares of its common stock as an upfront payment and to make potential additional milestone payments in cash or stock upon achievement of specified development, clinical and commercial milestones.

Stock listing and regulatory status

Beam Therapeutics Inc. lists its common stock, with a par value of $0.01 per share, on the Nasdaq Global Select Market under the trading symbol BEAM, as disclosed in its Form 8-K filings. The company’s SEC filings and press releases indicate ongoing operations as a clinical-stage biotechnology company focused on precision genetic medicines.

Corporate identity and values

Across its public communications, Beam describes itself as a values-driven organization committed to its people, its scientific platform and a vision of providing life-long cures to patients suffering from serious diseases. The company emphasizes a platform-driven approach in which progress in one program is intended to strengthen the foundation for subsequent programs, with a focus on precision, predictability and the potential for one-time genetic treatments.

Stock Performance

$21.66
+3.65%
+0.76
After hoursChange vs the $20.90 closeLast updated: at
+1.5%
Performance 1 year
103.5M
Shares outstanding As of October 27, 2026.

Beam Therapeutics (BEAM) closed at $20.90 on November 20, 2026. Over the past 12 months, the price has gained 1.5%.

See what a $1,000 investment in BEAM would be worth today

Average down calculator for BEAM

BEAM Metrics & Rankings

Price returns through November 20, 2026. Month and year figures include the first trading day. Ranking links may use different dates.

Latest News

Beam Therapeutics has 10 recent news articles. Of the recent coverage, 5 articles coincided with positive price movement and 5 with negative movement. Key topics include clinical trial, earnings. View all BEAM news →

Insider Radar

Net Sellers
90-Day Summary
0
Shares Bought
50,187
Shares Sold
3
Transactions
Most Recent Transaction
Evans John M. (CEO) sold 25,000 shares @ $23.98 on October 16, 2026

Insider selling at Beam Therapeutics over the past 90 days can reflect routine portfolio management, scheduled trading plans (Rule 10b5-1), tax planning, or compensation-related dispositions rather than a directional view on the stock.

Based on SEC Form 4 filings over the last 90 days.

Financial Highlights

Beam Therapeutics generated $139.7M in revenue in FY2025, operating income reached -$383.7M, and net income was -$80.0M, reflecting a -57.2% net profit margin. Diluted earnings per share stood at -$0.81. The company generated -$345.1M in operating cash flow. The current ratio was 13.09, measuring current assets divided by current liabilities.

$139.7M
Revenue (FY2025)
-$80.0M
Net Income (FY2025)
-$345.1M
Operating Cash Flow

Upcoming Events

DEC
12
December 12, 2026 Clinical

ASH oral presentation

Oral presentation of BEACON Phase 1/2 risto-cel results at ASH in New Orleans on Dec 12, 2026; selected for ASH press program.
Q4
2026
Q4 2026 Regulatory

Potential risto-cel BLA submission

Company reiterated possible BLA submission for risto-cel as early as year-end 2026
DEC
31
December 31, 2026 Regulatory

BLA submission expected

Beam expects U.S. Biologics License Application submission for risto-cel as early as year-end 2026, seeking regulatory approval.
DEC
31
December 31, 2026 Regulatory

Risto-cel application

Submission of risto-cel sickle cell disease application expected as early as year-end 2026; timing subject to readiness.
DEC
31
December 31, 2026 Regulatory

BLA submission for risto-cel

Planned BLA submission for risto-cel, stated as "as early as year-end 2026".
H2
2026
H2 2026 Regulatory

BEACON BLA expected

BLA expected as early as year-end 2026 for BEACON risto-cel; company may submit to FDA; details via investor materials.
DEC
31
December 31, 2026 Regulatory

Risto-cel BLA submission

Potential risto-cel BLA submission as early as year-end 2026 for SCD; company may file regulatory package by 2026-12-31.
YEAR
2027
2027 Clinical

Pivotal results presentation

Will present detailed pivotal BEACON Phase 1/2 results at a medical meeting in 2027; exact date, venue and webcast TBA.
YEAR
2027
2027 Clinical

Initial BEAM-304 dosing

Initial dosing of BEAM-304 anticipated in early 2027 (Jan–Apr window); clinical site and dosing details to be provided.
H1
2027
H1 2027 Clinical

Pivotal cohort completion

Completion of pivotal-cohort dosing expected in first half of 2027 (Jan–Jun); may affect pivotal data timing and milestones.
YEAR
2027
2027 Product

Risto-cel launch

Targeted potential launch of risto-cel in 2027 by Beam Therapeutics; timing contingent on regulatory approvals and commercial readiness.
AUG
17
August 17, 2027 Clinical

12-month biomarker readout

Anticipated 12-month AAT biomarker readout from the BEAM-302 global pivotal cohort, supporting planned U.S. accelerated approval.
YEAR
2033
2033 Financial

Credit facility maturity

Seven-year $500M facility matures in early 2033; secured by liens; mandatory prepayments.

Beam Therapeutics has 13 upcoming scheduled events. The next event, "ASH oral presentation", is scheduled for December 12, 2026 (in 20 days). 1 of them is a financing or capital event, such as a dividend or a debt maturity. Investors can track these dates to stay informed about potential catalysts that may affect the BEAM stock price.

Short Interest History

Last 12 Months

Short interest in Beam Therapeutics (BEAM) currently stands at 26.1 million shares, down 0.6% from the previous reporting period, representing 25.6% of the float. Since November 2025, short interest has increased by 24.5%.

Days to Cover History

Last 12 Months

Days to cover for Beam Therapeutics (BEAM) currently stands at 13.7 days. The ratio is the reported short interest divided by the average daily trading volume. Since November 2025, the figure has increased by 32.1%. Across the settlements charted above, it has ranged from 8.4 to 16.1 days.

BEAM Company Profile & Sector Positioning

Beam Therapeutics (BEAM) operates in the Biotechnology industry within the broader Healthcare sector and is listed on the NASDAQ.

Investors comparing BEAM often look at related companies in the same sector, including Pharvaris N.V. (PHVS), Celldex Therapeutics, Inc (CLDX), Palvella Therapeutics, Inc. (PVLA), MBX Biosciences, Inc. (MBX), and Arcus Biosciences, Inc. (RCUS). Comparing financial metrics, valuation ratios, and stock performance across these peers can help investors evaluate BEAM's relative position within its industry.

Frequently Asked Questions

The current stock price of Beam Therapeutics (BEAM) is $21.66 in after-hours trading as of November 20, 2026.

The market cap of Beam Therapeutics (BEAM) is approximately $2.2B. Learn more about what market capitalization means .

The FY2025 revenue of Beam Therapeutics (BEAM) is $139.7M, from its most recent completed fiscal year.

The FY2025 net income of Beam Therapeutics (BEAM) is -$80.0M, from its most recent completed fiscal year.

The diluted earnings per share (EPS) of Beam Therapeutics (BEAM) is -$0.81 for FY2025, its most recent completed fiscal year. Learn more about EPS .

The operating cash flow of Beam Therapeutics (BEAM) is -$345.1M for FY2025, its most recent completed fiscal year. Learn about cash flow.

The net profit margin of Beam Therapeutics (BEAM) is -57.2% for FY2025, its most recent completed fiscal year. Learn about profit margins.

The current ratio of Beam Therapeutics (BEAM), current assets divided by current liabilities, was 13.09 at the end of FY2025, its most recent completed fiscal year. Learn about liquidity ratios.

The operating income of Beam Therapeutics (BEAM) is -$383.7M for FY2025, its most recent completed fiscal year. Learn about operating income.

Beam Therapeutics Inc. is a biotechnology company developing precision genetic medicines through base editing. The company has assembled a platform with integrated gene editing, delivery and internal manufacturing capabilities and is using this platform to advance a diversified portfolio of base editing programs in hematology and genetic diseases.

Beam describes its base editing technology as a proprietary suite of gene editing tools designed to enable precise, predictable and efficient single base changes at targeted genomic sequences without making double-stranded breaks in DNA. The company states that this approach has the potential to support a wide range of therapeutic editing strategies.

Ristoglogene autogetemcel (risto-cel), formerly known as BEAM-101, is an investigational genetically modified ex vivo base editing cell therapy for sickle cell disease with severe vaso-occlusive crises. It consists of autologous CD34+ hematopoietic stem and progenitor cells that have been base-edited in the promoter regions of the HBG1/2 genes and are administered via a hematopoietic stem cell transplant procedure.

BEAM-302 is Beam’s lead liver-targeted genetic disease program. The company describes BEAM-302 as a liver-targeting therapy for alpha-1 antitrypsin deficiency (AATD) designed to address the underlying pathophysiology of both liver and lung disease. It is being evaluated in an open-label Phase 1/2 clinical trial in patients with AATD.

Beam has reported that the U.S. Food and Drug Administration granted Regenerative Medicine Advanced Therapy (RMAT) designation and orphan drug designation to BEAM-101 for sickle cell disease. The company has also disclosed that BEAM-302 received RMAT designation and orphan drug designation and that both risto-cel and BEAM-302 have been accepted into the FDA’s Chemistry, Manufacturing, and Controls Development and Readiness Pilot (CDRP) program.

The BEACON Phase 1/2 trial is an open-label, single-arm, multicenter clinical study evaluating risto-cel (formerly BEAM-101) in patients with sickle cell disease with severe vaso-occlusive crises. Beam has reported updated safety and efficacy data from this trial, including measures such as fetal hemoglobin induction, reductions in sickle hemoglobin, engraftment times and markers of hemolysis.

BEAM-301 is a program in Beam’s liver-targeted genetic disease franchise that aims to correct the R83C mutation in patients with glycogen storage disease type Ia (GSDIa). Beam states that BEAM-301 is being evaluated in an open-label Phase 1/2 dose-exploration trial in patients with GSDIa.

ESCAPE (Engineered Stem Cell Antibody Evasion) is a Beam platform intended to enable non-genotoxic treatment strategies in stem cell transplantation. BEAM-103 is an anti-CD117 monoclonal antibody developed as part of the ESCAPE platform and is being studied in a Phase 1 healthy volunteer trial. Beam describes ESCAPE as a potential alternative to genotoxic conditioning regimens for patients with sickle cell disease and beta-thalassemia.

Beam Therapeutics Inc. lists its common stock on the Nasdaq Global Select Market under the trading symbol BEAM, as disclosed in its Form 8-K filings.

Beam describes itself as a values-driven organization committed to its people, its scientific platform and a vision of providing life-long cures to patients suffering from serious diseases. The company emphasizes precision, predictability and a platform-driven approach to advancing precision genetic medicines.